(Q46682202)

English

Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

1 reference

based on heuristic

inferred from title

author name string

Rohit Borker

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Amanda Emmett

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Priti Jhingran

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Kathleen Rickard

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Paul Dorinsky

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Annals of Allergy, Asthma & Immunology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

95

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

181-189

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors and costs associated with an asthma attack

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychopathology in patients with severe asthma is associated with increased health care utilization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost of asthma in the emergency department and hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A Bayesian approach to stochastic cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Carrier screening for cystic fibrosis: costs and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Asthma guidelines: an assessment of physician understanding and practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961209-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1081-1206(10)61209-4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16136769

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46682202&oldid=2125961905"